💊 Zydus Lifesciences Q1 FY27: Strong Revenue Growth, But Margins Under Pressure 📊

Zydus Lifesciences delivered a strong revenue performance in Q1 FY27, supported by growth across India formulations, international markets and North America. 📈 Key Numbers 🔹 Revenue: ₹8,017 crore | +22% YoY 🔹 EBITDA: ₹1,929 crore | -7.6% YoY 🔹 EBITDA Margin: 24.1% vs 31.8% YoY 🔹 Reported PAT: ₹940 crore | -35.9% YoY 🔹 R&D: ₹642 crore | +32.3% YoY 🔹 Organic Capex: ₹585 crore 🇮🇳 India Formulations The branded business grew 20% YoY, continuing to outperform the Indian pharmaceutical market. Chronic and sub-chronic portfolio contribution reached 54.2%, improving by 360 bps over four years. 🇺🇸 North America The business remained resilient, supported by volume expansion and new launches. Zydus launched 11 new products, filed 5 ANDAs and received 9 ANDA approvals during the quarter. 🌍 International Markets International formulations revenue grew an impressive 34% YoY, driven by strong demand across emerging markets and Europe. 🚀 Innovation Pipeline Zydus received USFDA priority review for Saroglitazar Magnesium for PBC and continued clinical development across biosimilars, vaccines and novel therapies. 🎯 Investor Takeaway The topline momentum remains strong, with broad-based growth across major businesses. However, the sharp decline in EBITDA margin and PAT is the key monitorable. The next catalyst will be whether new launches, specialty products and volume growth can translate into margin recovery. ⚠️ Disclaimer: For educational purposes only. Not investment advice or a recommendation to buy/sell securities. !zyduslife